About the Company
oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ONCT News
ONCT Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical ...
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today ...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to Oncternal’s ...
Oncternal Therapeutics: Q4 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of ...
Q4 2023 Oncternal Therapeutics Inc Earnings Call
Richard Vincent; CFO; Oncternal Therapeutics, Inc. Jim Breitmeyer; President and CEO; Oncternal Therapeutics, Inc. Carl Byrnes; Analyst; Northland Capital Markets Hartaj Singh; Analyst; Oppenheimer & ...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies ...
Oncternal Therapeutics: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...
Oncternal Therapeutics Inc ONCT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 7, 2024 Oncternal Therapeutics, Inc. isn’t one of the 30 most popular stocks among ...
Loading the latest forecasts...